The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Open accessAbstract
Decay-accelerating factor (DAF), extracted from the stroma of human erythrocytes, was purified to homogeneity and incorporated into the membrane of sheep red cell complement intermediates, where its functional properties were analyzed. Incorporation of DAF into the cell membranes was temperature dependent, took place on pronase- or trypsin-treated erythrocytes, and did not depend on prior deposition of antibody, C1 or C4. Serum lipoproteins (high and low density) effectively inhibited DAF incorporation, but had no effect on the activity of DAF after its association with the cell membrane. The incorporated DAF could not be removed from the red cell surface by repeated washings in the presence of high salt concentration but was solubilized when the stroma were extracted with 0.1% Nonidet P-40. The presence of DAF in the membrane of EA did not affect the deposition of C1 and C4, but as few as 10(2) DAF molecules per cell profoundly inhibited the assembly of C3 and C5 convertases of both the classical and alternative pathways. The DAF inhibitory effect on EAC14 or EAC43 was not overcome by supplying an excess of C2 or factor B, but the alternative pathway C3 convertase could be assembled in the presence of Ni++, or nonphysiological concentrations of Mg++, which enhances the binding affinity of factor B for C3b. The DAF effect on EAC14 or EAC143 was entirely reversed by treating the cells with specific anti-DAF antibodies, showing that DAF did not alter the structure of C4b or C3b. Taken together, the experimental evidence suggests that DAF interacts directly with membrane-bound C3b or C4b and prevents subsequent uptake of C2 and factor B. DAF can function only within the cell membrane. Indeed, the decay dissociation of the C4b2a enzyme on DAF-containing sheep intermediates was not changed by varying the cell concentration. DAF-treated EA had no influence on the decay of nontreated EAC142 present in the same mixture. Moreover, the inhibitory activity of intact human erythrocytes on C4b2a was not blocked by antibodies to DAF, but was abolished by antibodies to the C3b/C4b receptor (CR1). When incorporated into the membrane of rabbit erythrocytes, human DAF inhibited their lysis by human complement. In conclusion, on the basis of these and previous results, it appears that DAF plays a central role in preventing the amplification of the complement cascade on host cell surfaces.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Fearon, D. T. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.11.5867 · Cited by 440
Nicholson-Weller, A., March, J. P., Rosenfeld, S. I., & Austen, K. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.16.5066 · Cited by 428
Fearon, D. T. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.4.1971 · Cited by 418
Molecular Biology and Chemistry of the Alternative Pathway of Complement
Müller-Eberhard, H. J., & Schreiber, R. D. (1980) · Advances in Immunology · doi:10.1016/s0065-2776(08)60042-5 · Cited by 408
Pangburn, M. K., & Müller-Eberhard, H. J. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.5.2416 · Cited by 346
Iida, K., Mornaghi, R., & Nussenzweig, V (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.5.1427 · Cited by 339
Self-citationGigli, I., Fujita, T., & Nussenzweig, V (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.12.6596 · Cited by 338
Self-citationMedof, M. E., Iida, K., Mold, C., & Nussenzweig, V (1982) · The Journal of experimental medicine · doi:10.1084/jem.156.6.1739 · Cited by 334
Self-citationPangburn, M. K., Schreiber, R. D., & Müller-Eberhard, H. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.17.5430 · Cited by 317
Ross, G. D., Lambris, J. D., Cain, J. A., & Newman, S. L. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.5.2051 · Cited by 293
Complement receptor is an inhibitor of the complement cascade.
Iida, K., & Nussenzweig, V (1981) · The Journal of experimental medicine · doi:10.1084/jem.153.5.1138 · Cited by 264
Self-citationTHE REACTION MECHANISM OF HUMAN C5 IN IMMUNE HEMOLYSIS
Cooper, N. R., & Müller‐Eberhard, H. J. (1970) · The Journal of Experimental Medicine · doi:10.1084/jem.132.4.775 · Cited by 188
Fearon, D., & Austen, K. (1977) · The Journal of Experimental Medicine · doi:10.1084/jem.146.1.22 · Cited by 177
PROPERDIN FACTOR D: CHARACTERIZATION OF ITS ACTIVE SITE AND ISOLATION OF THE PRECURSOR FORM
Fearon, D. T., Austen, K. F., & Ruddy, S. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.139.2.355 · Cited by 118
Fearon, D., Kaneko, I., & Thomson, G. G. (1981) · Journal of Experimental Medicine · doi:10.1084/jem.153.6.1615 · Cited by 100
Fishelson, Z., & Müller‐Eberhard, H. J. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.6.2603 · Cited by 96
Pangburn, M. K., Schreiber, R. D., Trombold, J. S., & Müller‐Eberhard, H. J. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.157.6.1971 · Cited by 93
Parker, C. J., Soldato, C. M., & Telen, M. J. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111472 · Cited by 34
[6] The second component of human complement
Kerr, M. A. (1981) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(81)80008-0 · Cited by 18
Cited by
Paroxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2014) · Blood · doi:10.1182/blood-2014-02-522128 · Cited by 648
“GPI-APs also serve as receptors forproaerolysin, apore-formingbacterial toxinsecretedbyAeromonas hydrophila(13,14); however, it is the absence of CD55 and CD59 that accounts for most of the clinical manifestations of PNH.(15,16) CD59 is a 19 000-Da glycoprotein that directly interacts with the membrane attack complex…”
Davies, A., Simmons, D. L., Hale, G., Harrison, R. A., Tighe, H., Lachmann, P. J., & Waldmann, H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.637 · Cited by 633
Strainic, M. G., Liu, J., Huang, D., An, F., Lalli, P. N., Muqim, N., Shapiro, V. S., Dubyak, G. R., Heeger, P. S., & Medof, M. E. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.001 · Cited by 580
Self-citationControl of the Complement System
Uszewski, M. K., Farries, T. C., Lublin, D. M., Rooney, I. A., & Atkinson, J. P. (1996) · Advances in Immunology · doi:10.1016/s0065-2776(08)60868-8 · Cited by 500
Holguin, M. H., Fredrick, L. R., Bernshaw, N. J., Wilcox, L. A., & Parker, C. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114172 · Cited by 403
Metadata
- Authors
- Medof, M. E., Kinoshita, T., & Nussenzweig, V
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1984-11-01
- Volume
- 160
- Issue
- 5
- Pages
- 1558-1578
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2104199760
- Cited by
- 561
- References
- 21
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.